Archive | April, 2009

Swine Flu fear boost Biotechs

The U.S. Government declared an emergency Sunday and released 25% of Relenza and Tamiflu antiviral treatment courses for use by healthcare providers should cases escalate. Tamiflu was developed by Gilead and manufactured and sold by Roche; Relenza is made by GlaxoSmithKline. A travel advisory to Mexico may be issued today where there are 2000 cases […]

Continue Reading 0

Macro Reflation trade: Deflation risk persists

An April 14 story on Bloomberg said that the ECB may have to lower interest rates below 1.25% next month to counter the worse recession in six decades. And the FED continued its quantitative easing Monday purchasing $7.37B in Treasuries and $5.15 B in Agency debt. Treasuries ended strong with the Ten Year Tsy Bond […]

Continue Reading 0

Q1 Biotechnology Update

The March rally improved the performance of the Life Science sector in Q1 but trailed gains in the technology sector. The S&P Healthcare Index lost 8.5% in Q1 compared to the S&P 500 loss of 11.7%. The S&P Technology Sector gained about 2% in 2009. The Rayno Life Science Portfolio was down only 2% including […]

Continue Reading 0